Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Gastric Cancer

Free Subscription Articles published in Eur J Cancer Retrieve available abstracts of 29 articles: HTML format Text format

Single Articles

November 2018
1. SAEKI H, Oki E, Kashiwada T, Arigami T, et al
   Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).
   Eur J Cancer. 2018;105:41-49.
   PubMed     Text format     Abstract available
   
   
   August 2018
2. NISHIKAWA K, Tsuburaya A, Yoshikawa T, Kobayashi M, et al
   A randomised phase II trial of capecitabine plus cisplatin versus S-1 plus cisplatin as a first-line treatment for advanced gastric cancer: Capecitabine plus cisplatin ascertainment versus S-1 plus cisplatin randomised PII trial (XParTS II).
   Eur J Cancer. 2018;101:220-228.
   PubMed     Text format     Abstract available
   
   
   March 2018
3. HEWITT LC, Inam IZ, Saito Y, Yoshikawa T, et al
   Epstein-Barr virus and mismatch repair deficiency status differ between oesophageal and gastric cancer: A large multi-centre study.
   Eur J Cancer. 2018;94:104-114.
   PubMed     Text format     Abstract available
   
   
   
4. ROVIELLO F, Polom K, D'Ignazio A, Pascale V, et al
   Potential impact of molecular classification on tailored lymphadenectomy for gastric cancer.
   Eur J Cancer. 2018;92 Suppl 2:S8.
   PubMed     Text format    
   
   
   
5. CHIAPPA A, Bertani E, Fazio N, Foschi D, et al
   D2-lymphadenectomy and gastric resection in a consecutive series of patients with gastric cancer.
   Eur J Cancer. 2018;92 Suppl 2:S7.
   PubMed     Text format    
   
   
   
6. BENCIVENGA M, Treppiedi E, Verlato G, Mengardo V, et al
   The amount of cells with Signet Ring Cell morphology has a prognostic impact in poorly cohesive gastric carcinoma.
   Eur J Cancer. 2018;92 Suppl 2:S6.
   PubMed     Text format    
   
   
   
7. ROVIELLO F, Polom K, D'Ignazio A, Pascale V, et al
   K-RAS mutation in gastric cancer and its link with microsatellite instability status.
   Eur J Cancer. 2018;92 Suppl 2:S6.
   PubMed     Text format    
   
   
   
8. CARNEIRO F
   Hereditary gastric cancer.
   Eur J Cancer. 2018;92 Suppl 2:S4.
   PubMed     Text format    
   
   
   
9. ROVIELLO F
   The role of HIPEC in gastric cancer.
   Eur J Cancer. 2018;92 Suppl 2:S4-S5.
   PubMed     Text format    
   
   
   
10. TERASHIMA M
    Perioperative treatment strategies and current studies to improve gastric cancer outcomes in Japan.
    Eur J Cancer. 2018;92 Suppl 2:S3.
    PubMed     Text format    
    
    
    
11. LORDICK F
    Response-adapted treatment stratification in oesophago-gastric cancer.
    Eur J Cancer. 2018;92 Suppl 2:S3.
    PubMed     Text format    
    
    
    
12. LAURENT-PUIG P
    Oesophago-gastric cancer: One disease or separate entities?: Translating molecular subtyping into clinical practice.
    Eur J Cancer. 2018;92 Suppl 2:S1.
    PubMed     Text format    
    
    
    
13. NASR F, El Rassy E, Maalouf G, Azar C, et al
    Severe ophthalmoplegia and myocarditis following the administration of pembrolizumab.
    Eur J Cancer. 2018;91:171-173.
    PubMed     Text format    
    
    
    February 2018
14. SPOERL S, Novotny A, Al-Batran SE, Lordick F, et al
    Histopathological regression predicts treatment outcome in locally advanced esophagogastric adenocarcinoma.
    Eur J Cancer. 2018;90:26-33.
    PubMed     Text format     Abstract available
    
    
    January 2018
15. BANDO H, Shimodaira H, Fujitani K, Takashima A, et al
    A phase II study of nab-paclitaxel in combination with ramucirumab in patients with previously treated advanced gastric cancer.
    Eur J Cancer. 2018;91:86-91.
    PubMed     Text format     Abstract available
    
    
    December 2017
16. WANG H, Li B, Liu Z, Gong J, et al
    HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer.
    Eur J Cancer. 2017;88:92-100.
    PubMed     Text format     Abstract available
    
    
    August 2017
17. COURTOIS S, Duran RV, Giraud J, Sifre E, et al
    Metformin targets gastric cancer stem cells.
    Eur J Cancer. 2017;84:193-201.
    PubMed     Text format     Abstract available
    
    
    
18. STAHL M, Walz MK, Riera-Knorrenschild J, Stuschke M, et al
    Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial.
    Eur J Cancer. 2017;81:183-190.
    PubMed     Text format     Abstract available
    
    
    
19. KWAKMAN JJM, Baars A, van Zweeden AA, de Mol P, et al
    Case series of patients treated with the oral fluoropyrimidine S-1 after capecitabine-induced coronary artery vasospasm.
    Eur J Cancer. 2017;81:130-134.
    PubMed     Text format    
    
    
    July 2017
20. PARK SR, Kim MJ, Nam BH, Kim CG, et al
    A randomised phase II study of continuous versus stop-and-go S-1 plus oxaliplatin following disease stabilisation in first-line chemotherapy in patients with metastatic gastric cancer.
    Eur J Cancer. 2017;83:32-42.
    PubMed     Text format     Abstract available
    
    
    
21. KEMPF E, Tournigand C, Rochigneux P, Aubry R, et al
    Discrepancies in the use of chemotherapy and artificial nutrition near the end of life for hospitalised patients with metastatic gastric or oesophageal cancer. A countrywide, register-based study.
    Eur J Cancer. 2017;79:31-40.
    PubMed     Text format     Abstract available
    
    
    
22. PERNOT S, Badoual C, Terme M, Castan F, et al
    Dynamic evaluation of circulating tumour cells in patients with advanced gastric and oesogastric junction adenocarcinoma: Prognostic value and early assessment of therapeutic effects.
    Eur J Cancer. 2017;79:15-22.
    PubMed     Text format     Abstract available
    
    
    June 2017
23. D'AMBROSIO L, Palesandro E, Boccone P, Tolomeo F, et al
    Impact of a risk-based follow-up in patients affected by gastrointestinal stromal tumour.
    Eur J Cancer. 2017;78:122-132.
    PubMed     Text format     Abstract available
    
    
    
24. HAJ MOHAMMAD N, Bernards N, van Putten M, Lemmens VEPP, et al
    Volume-outcome relation in palliative systemic treatment of metastatic oesophagogastric cancer.
    Eur J Cancer. 2017;78:28-36.
    PubMed     Text format     Abstract available
    
    
    May 2017
25. FARAG S, Somaiah N, Choi H, Heeres B, et al
    Clinical characteristics and treatment outcome in a large multicentre observational cohort of PDGFRA exon 18 mutated gastrointestinal stromal tumour patients.
    Eur J Cancer. 2017;76:76-83.
    PubMed     Text format     Abstract available
    
    
    
26. PETRELLI F, Tomasello G, Barni S
    Surrogate end-points for overall survival in 22 neoadjuvant trials of gastro-oesophageal cancers.
    Eur J Cancer. 2017;76:8-16.
    PubMed     Text format     Abstract available
    
    
    April 2017
27. DESIDERIO J, Chao J, Melstrom L, Warner S, et al
    The 30-year experience-A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer.
    Eur J Cancer. 2017;79:1-14.
    PubMed     Text format     Abstract available
    
    
    February 2017
28. IENI A, Angelico G, Zeppa P, Tuccari G, et al
    Letter to the Editor regarding the paper by Park et al., Extra-gain of HER2-positive cases through HER2 reassessment in primary and metastatic sites in advanced gastric cancer with initially HER2-negative primary tumours: Results of GASTric cancer HER
    Eur J Cancer. 2017;75:190-191.
    PubMed     Text format    
    
    
    December 2016
29. OH HJ, Lim CH, Yoon BH, Yoon SB, et al
    Fracture after gastrectomy for gastric cancer: A long-term follow-up observational study.
    Eur J Cancer. 2016;72:28-36.
    PubMed     Text format     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Gastric Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: